Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord Genuity 45th Annual Growth Conference, on Tuesday, August 12, 2025 at 8:00 am ET. A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
Related Questions
Will management address the competitive landscape for RNAi therapeutics and how Alnylam differentiates itself?
Will the webcast provide insight into cost‑structure or margin improvements for upcoming product launches?
Does Alnymil plan to discuss partnerships, licensing deals, or collaborations that could impact future revenues?
How might this investor event influence short‑term trading volume and price volatility?
Are there any upcoming regulatory milestones or trial results mentioned that might move the price?
Could the event trigger re‑rating or target‑price changes from broker analysts?
Will the conference presentation provide any new data or updates on Alnylam's pipeline that could affect the stock?
Is there any guidance or financial outlook to be shared during the webcast that could shift analyst expectations?
How does this event compare to prior Alnylam investor conferences in terms of market impact?
What is the market's likely reaction if Alnylam announces setbacks or positive milestones in the presentation?